TNGX - Tango Therapeutics Inc logo

Tango Therapeutics Inc

TNGX

Tango Therapeutics develops precision oncology drugs targeting specific patient populations. Its pipeline includes PRMT5 inhibitors for pancreatic, lung, and glioblastoma cancers, along with therapies aimed at reversing immune evasion in lung cancer.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$2,072today

Score Overview

1 Year
Score
Net Growth-21.78%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-13.74%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.7
Net Growth-112.45%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth45.27%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth-138.05%
Net Trend33%
Net Income Consistency
Rev Growth7x
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Tango Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. TNGX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 26.98โ€”
1 Year2025-10-21
$ 8.99200.11%
5 Years2021-10-21
$ 13.02107.22%
All Time2020-09-03
$ 10.23163.73%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 53M-$ 123M$ 1.01B
2025$ 62M-$ 101M$ 343M
2024$ 42M-$ 130M$ 257M
2023$ 36M-$ 101M$ 336M
2022$ 24M-$ 108M$ 366M
2021$ 37M-$ 58M$ 485M
IPO2020$ 7M-$ 51M$ 190M
TNGX - Tango Therapeutics Inc logo

Tango Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 7M to $ 62M and net income went from -$ 51M to -$ 101M. Revenue increased in 3 of those 5 years; net income in 2.

Tango Therapeutics Inc currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.

Membership

Explore TNGX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies